Orphan Drugs: Hope Where There Is Little or No Hope

NEW YORK, N.Y., February 18, 2004 ? On a visit to his doctor, Gary Jacob received distressing news ? not about himself, but a friend of the doctor's.

While playing with one of his children, the doctor's friend fell and broke a rib. That was bad enough, but during the examination at the hospital, the father was hit with a startling and totally unexpected diagnosis ? he had a disease known as multiple myeloma, a bone marrow blood cancer.

The diagnosis was nothing less than a death sentence.

Jacob knew of the anguish of multiple myeloma patients. The disease is incurable and nearly always fatal, one of the rare diseases that have few, if any, available treatments. They are known as "orphan" diseases, shunned by most drug-makers because the patient populations are small and commercial development of a drug is seen as economically unattractive.

Mr. Jacob was aware because, as Chief Executive Officer of Callisto Pharmaceuticals, Inc., a small Manhattan-based biopharmaceutical company, he is leading a scientific effort to develop a new orphan drug called "Atiprimod" for multiple myeloma patients.

"The father's disease brought home to me that what we are doing is really important," says Mr. Jacob. "Everyone agrees we need more drugs to treat multiple myeloma. There are people out there dying without real hope because of a lack of effective treatment for all patients."

In steadily increasing numbers, orphan drugs are providing new doses of hope where little or none at all existed. In the decade before the inception of the federal Food and Drug Administration's orphan drug program, 10 drugs were developed by pharmaceutical companies for orphan diseases. In the decades since, the FDA says nearly 250 new drugs were developed and approved, and hundreds more are in the pipeline.

Atiprimod is one of those wending its way toward the marketplace. Callisto recently obtained orphan drug designation from the FDA, providing the company with financial incentives to continue the costly development process.

The program covers drugs for orphan diseases with patient populations under 200,000.

The National Organization for Rare Disorders reports about 25 million people in the United States suffer from an estimated 6,000 orphan diseases.

Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher's disease, hemophilia and rare forms of cancer were among the orphans without effective medicines until the FDA program went into effect in 1983 and paved the way for new drugs for patients with these diseases.

Large drug-makers have been largely missing from the efforts.

According to the orphan drug program's deputy director, Dr. John McCormick, only 15% of applications for orphan drug designation have come from the larger pharmaceutical companies.

The reason: expectations of unfavorable investment returns.

The FDA orphan drug incentives ? grants, seven years of marketing exclusivity and tax breaks ? have drawn small pharmaceutical companies with promising drug candidates into the breach.

While the future is brighter, the task is still daunting to develop drugs for orphan diseases.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington's disease also affects about 30,000 patients.

Some diseases affect fewer than 100 patients, according to the National Institutes of Health.

An estimated 50,000 patients have multiple myeloma with 15,000 new patients diagnosed each year. Last year, the FDA approved a new drug Velcade for patients with the disease. However, there are still a number of multiple myeloma patients with no treatment available.

Dr. Kenneth C. Anderson, who played a major role in the preclinical development and clinical trials of Velcade and is now a member of Callisto's Medical Advisory Board, is among the experts who see a need for more drugs to treat multiple myeloma.

"He is excited to see Atiprimod enter clinical trials for evaluation in multiple myeloma patients," Jacob said of Anderson. "He believes it has an opportunity to help patients who have not responded to other drugs. "

Dr. Anderson is director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute in Boston, MA, and Professor of Medicine at Harvard Medical School.

The Phase I/IIa trials for Atiprimod are slated to begin later this month.

Dr. Donald Picker, Callisto's Senior Vice President of Drug Development, said studies of Atiprimod in collaboration with scientists at the National Cancer Institute have been very promising.

"In essence, we've shown in these early studies that Atiprimod has the potential to intervene with cancer cells and tumors in three ways ? by inhibiting their formation, by programming their death and by limiting their ability to grow blood vessels necessary for their survival. Taken together, these findings suggest that Atiprimod could potentially represent a novel class of compounds for development for therapeutic intervention in human cancers," said Dr. Picker.

About The Author

Alex Michelini is a former award-winning reporter/editor at the New York Daily News. His credits include nomination for a Pulitzer Prize for a series on medical costs. Among his honors, Mr. Michelini received the Deadline Club Award, the Page One Award, the Associated Press Award and the New York Press Club Award (twice). He is the founder of Alex Michelini Public Relations, and has developed and collaborated on articles appearing in the New York Times, the Wall Street Journal, the London Times, the New York Post, the New York Daily News, Bloomberg Radio & TV, CNNfn, WCBS Radio & TV. WINS radio, the Christian Science Monitor, Fox TV, Reuters, Newsday and other media outlets.

michelinialex@aol.com

When Your John Doe Is Homeless

The patient, known only as John Doe, was difficult to... Read More

Heel Pain - Ten Tips for Treatment

The most common cause of heel pain is plantar fasciitis... Read More

Hacking through the Medical Scheduling Software Jungle: Helpful Search Tips

It is the reality of the 21st century medical practice... Read More

Resperate or RESPeRATE - this device controls blood pressure however you spell it!

Resperate is natural and powerful and it puts you in... Read More

The Medical Community Changes Its Mind

How many of us have taken aspirin or a similar... Read More

Technology Over Drugs for Stress Related Tension Disorders

As much as 95% of the population suffers from some... Read More

Top Five FAQs About Nail Fungus

What is nail fungus?Nail fungus, also known as Onychomycosis, is... Read More

Clinton on South Beach Diet

Clinton's recent quadruple bypass surgery has been largely debated. Being... Read More

After Viagra, Its Now a Premature Orgasm Pill for Women

Pfizer's exciting drug history traces back to the most popular... Read More

New Company Helps Another Medical Condition Become: ?Acceptable? Dinner Conversation

Recently once taboo subjects like plastic surgery have become acceptable... Read More

Vioxx Side Effects : Are You Suffering?

Have you ever taken the drug Vioxx or celebrex? In... Read More

Prescription Drug Side Effects: Treating From The Outside Or The Inside?

Throughout time there have always been two opposing points of... Read More

A Very Medical Miracle

Madeline Mann once weighed less can a can of soda... Read More

How to Find a Drug Rehab in Florida?

When you're in need, the quickest way is the best:... Read More

Treatment for High Blood Pressure

The treatment of high blood pressure is one of the... Read More

Orthotics and Your Feet

Orthotics are devices which fit into the shoe to aid... Read More

The Last Line of Defense Against Medication Errors: What You Need to Know to Keep your Family Safe

This is a true story.Yesterday, I picked up a new... Read More

Robotic Future of Hospitals; Pandemic Prevention and Bio-Terrorist Attack

There is a huge concern in the medical industry that... Read More

An Introduction to Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a very common condition, but... Read More

Healthcare Providers -- Its Time for Your Physical

I think this is a good time for a checkup,... Read More

Why Modern Medicine is the Greatest Threat to Health

There is the underlying assumption that modernity translates into better... Read More

Hypnotherapy as a Treatment for IBS

Hypnotherapy is one of the best known and most widely... Read More

Stevens Johnson Syndrome Lawyer Says: Get Help

SJS is an allergic reaction to certain medications that can... Read More

10 Reasons To Buy Drugs From An Online Canadian Pharmacy

1. Online Canadian pharmacies offer overall best prices on Canadian... Read More

Could This Be Arthritis In My Hands

Hi Rusty. A few days ago, I slightly injured a... Read More